Experience with the use of baricitinib in the treatment of atopic dermatitis in HIV-infected patients
- Authors: Evdokimov E.Y.1, Ponezheva Z.B1, Svechnikova E.V2,3, Gruzdev B.M4
-
Affiliations:
- Central Research Institute of Epidemiology
- Polyclinic № 1 of the Administrative Department of the President of the Russian Federation
- Novosibirsk State Medical University
- Infectious Clinical Hospital № 2 of the Moscow Healthcare Department
- Issue: Vol 29, No 10 (2022)
- Pages: 26-30
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321081
- DOI: https://doi.org/10.18565/pharmateca.2022.10.26-30
- ID: 321081
Cite item
Open Access
Access granted
Abstract
Background. Among HIV-infected patients, atopic dermatitis (AD) occurs more frequently by 30% than in patients without HIV infection, and is characterized by severe dermatological symptoms and severe skin itch. For this reason, the treatment of AD and pruritus in HIV-infected patients remains relevant. Objective. Evaluation of the possibility of using the baricitinib in HIV-infected patients with AD. Methods. 6 HIV-infected patients with AD were followed-up; all patients received antiretroviral therapy (ART). There were 4 men (66.7%), 2 women (33.3%). The median age was 32.7 years (21-43). The mean duration of AD was 14.5 years (min - 7.1 years, max - 22). SCORAD - 74.8 (min - 28, max - 89). The mean duration of HIV infection was 3.8 years (min - 0.7 years, max - 11 years), the duration of ART averaged 3.4 years (min - 0.5 years, max - 9.6). All patients were examined before prescribing baricitinib. Results. In HIV-infected patients with AD, a pronounced clinical improvement in the general condition, a significant decrease in skin itching, and a decrease in the intensity of dermatological symptoms were noted after 12 weeks. There was no deterioration in the indicators of HIV infection (clinical course, decrease in the number of CD4+ lymphocytes, an increase in the viral load of HIV). Conclusion. Baricitinib in HIV-infected patients can be used for the treatment moderate to severe AD.
Keywords
Full Text
About the authors
Evgeny Yu. Evdokimov
Central Research Institute of Epidemiology
Email: evdokimovevg@yandex.ru
Cand. Sci. (Med.), Researcher at the Clinical Department Moscow, Russia
Zh. B Ponezheva
Central Research Institute of EpidemiologyMoscow, Russia
E. V Svechnikova
Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical UniversityMoscow, Russia; Russia
B. M Gruzdev
Infectious Clinical Hospital № 2 of the Moscow Healthcare DepartmentMoscow, Russia
References
- Kowalska-Olędzka E., Czarnecka M., Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126-28. doi: 10.1080/21556660.2019.1619570
- Евдокимов Е.Ю., Понежева Ж.Б., Сундуков А.В., Свечникова Е.В. Клинические и микробиологические особенности атопического дерматита у ВИЧ позитивных больных. Фарматека. 2020;27(8):13-23. doi: 10.18565/pharmateca.2020.8.18-23.
- Siberry G.K., Leister E., Jacobson D.L., et. al. Increased risk of asthma and atopic dermatitis in perinatally HIV-infected children and adolescents. Clinlmmunol. 2012;142(2):201-8. doi: 10.1016/j.clim.2011.10.005.
- Peter J., Choshi P., Lehloenya R.J. Drug hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol. 2019;19(4):272-282. doi: 10.1097/ACI.0000000000000545.
- Аверьянов А.В., Сотникова А.Г., Лесняк В.Н. (2020). Пневмоцистная пневмония, мимикрирующая под COVID-19. Клиническая практика. 2020;11(2):87-92.
- de Armas L.R., Gavegnano C., Pallikkuth S., The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency Front Immunol. 2021;12:72 0697. doi: 10.3389/fimmu.2021.720697.
- Адаскевич В.П. Диагностические индексы в дерматологии. М.: Издательство Панфилова; БИНОМ. Лаборатория знаний; 2014. 352 с.
- Common Terminology Criteria for Adverse Events v4.0 (CTCAE) Publish Date: 2009;28.
- Reich A., Heisig M., Phan N.Q., et. al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497-501. doi: 10.2340/00015555-1265.
- Choi J., Cooper M.L., Staser K., et. al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32(11):2483-94. doi: 10.1038/s41375-018-0123-z.
- Ghoreschi K., Laurence A., O'Shea J.J. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x.
Supplementary files
